The Future of Biopharmaceuticals

Amicus Therapeutics is a rising pioneer in the Biotechnological world. Amicus experts carefully examine biological processes to create advanced technology and medicine to better the health and longevity of those suffering from rare illness.


Amicus Therapeutics specializes in rare, orphan conditions. These are conditions that are present in a select population of the world, around 200,000 people. Although these conditions are rare they present dire consequences for all those who are infected. Some of the primary conditions include Fabry disease, Pompe disease and the rare skin condition known as Epidermolysis Bullosa. Amicus Therapeutics takes a righteous stand against these conditions, a position other Biotech companies have feared to approach.


Amicus has experienced exponential progress regarding the development of solutions for these conditions. Fabry disease is a genetic lysosomal disorder which causes an excessive accumulation of fat in the body which causes cell impairment in various areas of the body ( Amicus Therapeutics is in the late stages of development on the drug known as “Migalastat”, designed to combat the effects of Fabry disease. Epidermolysis Bullosa, a rare skin condition is also being targeted by Amicus. Nearing completion is a topical ointment currently known as SD-101, which will be used to treat the symptoms of Epidermolysis Bullosa. SD-101 has already “received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA)” as well as, “orphan drug designation from the FDA and European Medicines Agency (EMA)” (Amicusrx). Amicus Therapeutics is also developing state of the art enzyme replacement therapy products for all conditions including Pompe Disease (Facebook).


Orphan conditions are a rare sight in this world but their severe consequences drastically affect the lives of those infected. Amicus strives to be at the forefront of the battle against these conditions, bringing modern, effective technology to combat their life-threatening effects.

More about Amicus Therapeutics on Crunchbase

Leave a Reply

Your email address will not be published. Required fields are marked *


Hi, guest!